Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III [Yahoo! Finance]
Structure Therapeutics Inc. (GPCR)
Company Research
Source: Yahoo! Finance
mg) and 15.0% (240 mg) at week 44, with placebo-adjusted reductions near for the 180 mg and 240 mg arms and strong categorical responses (93% =10% loss and 61% =15% at 180 mg). Tolerability favored the 180 mg dose (similar to 120 mg) versus higher GI events at 240 mg, with a low overall discontinuation rate (~3.7%), no serious adverse events after re-randomization, and no signals of drug-induced liver injury (DILI) or QTc prolongation in the dataset. Structure plans an end-of-Phase II meeting with the FDA in Q2 and remains on track to initiate Phase III in the second half of the year, with multiple additional readouts and parallel amylin small-molecule programs advancing through Phase I in 2026. Interested in Structure Therapeutics Inc. Sponsored ADR? Here are five stocks we like better. 3 Companies at the Forefront of the GLP-1 Pill Wars Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an oral small-molec
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (GPCR) was given a new $145.00 price target by BMO Capital Markets. They now have an "outperform" rating on the stock.MarketBeat
- Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition Target [Seeking Alpha]Seeking Alpha
- Structure Therapeutics (GPCR) had its "outperform" rating reaffirmed by William Blair.MarketBeat
- Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 Transcript [Seeking Alpha]Seeking Alpha
- Structure Therapeutics (GPCR) had its price target lowered by HC Wainwright from $114.00 to $100.00. They now have a "buy" rating on the stock.MarketBeat
GPCR
Sec Filings
- 3/16/26 - Form 8-K
- 3/5/26 - Form 4
- 3/5/26 - Form 4
- GPCR's page on the SEC website